- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2031
- U.S. locations
- 259
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 196 more
Location Directory
Clinical trials in Jacksonville, Florida
This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7627
Shown on this page
12
Current sort
Recently updated
Location scope
Jacksonville, FL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 349–360 of 7,627 matching trials in Jacksonville, FL.
Live ClinicalTrials.gov results.
Institutions in Jacksonville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Newly Diagnosed Multiple Myeloma (NDMM)
- Interventions
- AZD0120, Cyclophosphamide, Fludarabine, Melphalan (part of ASCT), Lenalidomide
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2039
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 37 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
- Drug · Behavioral
- Lead sponsor
- Usona Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
- Conditions
- Oligometastatic Prostate Cancer (OMPC)
- Interventions
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 39
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- AAA617, ARPI: Abiraterone, ARPI: Enzalutamide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Elafibranor 80mg, Placebo
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 46
- States / cities
- Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more
- Conditions
- Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma, Ann Arbor Stage III Childhood Lymphoblastic Lymphoma, Ann Arbor Stage IV Adult Lymphoblastic Lymphoma, Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma, Childhood T Acute Lymphoblastic Leukemia
- Interventions
- Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Radiation Therapy, Thioguanine, Vincristine, Vincristine Sulfate
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 847 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 188
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 143 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more
- Conditions
- Acute Ischemic Stroke
- Interventions
- RapidPulseTM Aspiration System
- Device
- Lead sponsor
- RapidPulse, Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 18
- States / cities
- Torrance, California • New Haven, Connecticut • Jacksonville, Florida + 15 more
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Carboplatin, Computed Tomography, Paclitaxel, Pembrolizumab, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more
- Conditions
- Heart Failure
- Interventions
- Baxdrostat and dapagliflozin, Placebo and dapagliflozin
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 11,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 217
- States / cities
- Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 188 more
- Conditions
- Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
- Interventions
- Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
- Device · Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 23
- States / cities
- Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more